Articles related to BIOMARKERS

A Veterans Health Administration analysis of 4,890 men with metastatic hormone-sensitive prostate cancer found that achieving a PSA level below 0.2 ng/mL within 9 months was associated with improved survival. The retrospective findings support a threshold previously identified in clinical trials.

Researchers identified distinct neuronal populations within the heart’s intrinsic nervous system that regulate cardiac rhythm and stress responses in mice. The findings provide mechanistic insight into cardiac neurobiology, though human relevance remains uncertain.

In a single-center cross-sectional study of 75 symptomatic patients, coronary artery calcium score and carotid intima-media thickness were associated with CT-derived CAD severity. The findings support risk-stratification interest but require prospective validation.

Recordings from four Parkinson’s disease patients linked cuneiform and pedunculopontine nuclei activity to distinct phases of gait initiation. Freezing episodes were preceded by disrupted mesencephalic timing, though clinical translation remains early.

A randomized noninferiority trial involving 648 men with MRI-visible prostate lesions found that cognitive fusion biopsy achieved clinically significant prostate cancer detection rates similar to software-based fusion biopsy. Subgroup analyses suggested body mass index may influence the relative performance of each approach.

A two-year analysis of 12,670 screened men found that the Stockholm3 risk model detected more clinically significant prostate cancers than PSA testing alone, primarily through fewer false-negative results. The findings suggest improved screening discrimination, although follow-up remains limited to two years.